Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Physical injury rate (broken bones, wounds, etc) after initiating on GLP-1s vs other medications for T2D or obesity
Discover Liposomal Glutathione with advanced liposomal delivery for superior absorption
Oral GLP-1s have low bioavailability, around 0.4 to 1 percent, meaning the tablet needs to remain intact to navigate the stomach efficiently
30.3% at 104 weeks in a BMI 35 extension cohort TRANSCEND-T2D-1 confirmed (topline March 2026, published June 2026): First completed diabetes-specific Phase 3 trial -2.0% HbA1c and 16.8% weight loss in 537 patients, a separate program from TRIUMPH Filing timeline updated: Eli Lilly will submit a Biologics License Application (BLA) not an NDA, since retatrutide is a biologic now expected Q1 2027 (shifted from the previously estimated Q4 2026) OSA data confirmed (ADA June 6, 2026): TRIUMPH-1's nested sleep apnea substudy showed 60.6% AHI reduction from a severe-OSA baseline of 58.6 events/hour This page updates after every trial announcement bookmark for the latest Introduction Retatrutide stands at the forefront of obesity medicine a first-in-class triple hormone agonist that has demonstrated some of the highest weight loss efficacy ever recorded in clinical trials
Chao, J
US$ 20.43
US$ 24.30
US$ 25.81
US$ 26.97
US$ 29.92
US$ 24.06
US$ 22.28
US$ 21.55
US$ 25.57
